drugset

drugset / Trial / NCT06439056

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

NCT06439056 ↗

Phase 1 Completed 12 enrolled Nanexa AB Profil Institut für Stoffwechselforschung GmbH · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose with the study is to assess pharmacokinetics of NEX-22A in patients with type 2 diabetes.

Timeline

Start: 2024-05-27
Primary completion: 2025-07-18
Completion: 2025-07-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	—	Subcutaneous

Indications